PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
about
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesPlasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.Effects of LDL Receptor Modulation on Lymphatic FunctionBiology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes.The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.PCSK9 and carbohydrate metabolism: A double-edged sword.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
P2860
Q27009477-6BE6B9E0-8585-4BE2-8970-47BB5CC82773Q34321484-12FCE6DA-BE79-4EAC-9D2A-0238707E25DDQ34530204-F82783C8-F963-4183-AB93-F35916412214Q34536594-E0D06A85-2F89-40CD-AC6E-1CE5E30608DBQ36197840-023DF217-7C17-4B77-AF24-B2F60ACE4669Q37367952-EF593831-C9A5-408E-8CAE-B3DD720C4039Q37607330-1C7634B7-AB78-4F19-B52A-EDA2FA16DF0BQ37789741-7B1E4066-8D14-499B-BEA4-90E98D76468AQ37880856-AE6E6A3A-84B2-46CE-90CB-24679F8464A7Q38095872-6B168DC6-DFF0-4148-B154-84E367C21065Q38424373-0579A628-27E8-4ED9-AD27-1623CD16B825Q38796312-8A4AF878-4E8B-42BC-9B4C-7089D9F4A3B7Q39030028-9C7B58AE-0885-4500-B268-B056169608FAQ39453691-C58CD106-5294-4D78-8A0C-938F2940DC3EQ40532465-E5F09616-DA2B-4F93-BC15-5D6AEC5C05B0Q40863199-87EC6445-1B08-48EA-9706-8B395A83BA45Q42333207-82F4C205-BC47-4987-A13D-22B5C6ACBB43Q44847105-08ED066F-DA7B-4B6B-AAA9-5DBADC902AD4Q52721601-DCE69475-8F53-4573-AF09-78EBE7DA9188
P2860
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
@en
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
@nl
type
label
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
@en
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
@nl
prefLabel
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
@en
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.
@nl
P2093
P1476
PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion
@en
P2093
Bertrand Cariou
Brigitte Vandewalle
Cédric Langhi
Cédric Le May
Julie Kerr-Conte
Michel Krempf
Philippe Costet
Valéry Gmyr
P304
P356
10.1016/J.BBRC.2009.10.138
P407
P577
2009-10-28T00:00:00Z